Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Identifieur interne : 006271 ( Main/Exploration ); précédent : 006270; suivant : 006272Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Auteurs : Cedarbaum [États-Unis] ; Mary Clark [États-Unis] ; Linda H. Toy [États-Unis] ; Alison Green-Parsons [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1990.
Descripteurs français
- Wicri :
- topic : Thérapeutique.
English descriptors
- KwdEn :
- Activities of Daily Living, Antiparkinson Agents, Brain (drug effects), Carbidopa (administration & dosage), Carbidopa (adverse effects), Delayed-Action Preparations, Dopamine Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Combinations, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Oxazines (administration & dosage), Oxazines (adverse effects), Parkinson Disease (drug therapy), Parkinson's disease, Receptors, Dopamine (drug effects), Receptors, Dopamine D2, Response fluctuation, Therapeutics.
- MESH :
- chemical , administration & dosage : Carbidopa, Levodopa, Oxazines.
- chemical , adverse effects : Carbidopa, Levodopa, Oxazines.
- chemical , drug effects : Receptors, Dopamine.
- chemical : Antiparkinson Agents, Delayed-Action Preparations, Dopamine Agents, Drug Combinations, Receptors, Dopamine D2.
- drug effects : Brain.
- drug therapy : Parkinson Disease.
- Activities of Daily Living, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans.
Abstract
4‐‐Propyl‐9‐hydroxynaphthoxazine, or MK‐458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained‐release form, was studied as adjunctive therapy with carbidopa‐levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The dosage of agonist was gradually increased over 12 weeks to a maximum tolerated level of up to 60 mg/day, and that of Sinemet was reduced concurrently. After 8 weeks, reduction of Sinemet averaged 45.1%, but over the next 4 weeks, despite a continued increase in dosage of the agonist, patients were unable to decrease their Sinemet further, and by 12 weeks mean reduction in Sinemet was only 32%. Only five patients completed the planned 24‐week study, mostly due to progressive loss of efficacy. The MK‐458 is capable of partially substituting for Sinemet in dosages employed in this study. Reduced sensitivity to the drug can appear over a relatively short time, perhaps as a result of downregulation of postsynaptic dopamine receptors.
Url:
DOI: 10.1002/mds.870050407
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F74
- to stream Istex, to step Curation: 001F74
- to stream Istex, to step Checkpoint: 004360
- to stream PubMed, to step Corpus: 004F41
- to stream PubMed, to step Curation: 004F41
- to stream PubMed, to step Checkpoint: 004E74
- to stream Ncbi, to step Merge: 002841
- to stream Ncbi, to step Curation: 002841
- to stream Ncbi, to step Checkpoint: 002841
- to stream Main, to step Merge: 009605
- to stream Main, to step Curation: 006271
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation</title><author><name sortKey="Cedarbaum" sort="Cedarbaum" uniqKey="Cedarbaum" last="Cedarbaum">Cedarbaum</name></author><author><name sortKey="Clark, Mary" sort="Clark, Mary" uniqKey="Clark M" first="Mary" last="Clark">Mary Clark</name></author><author><name sortKey="Toy, Linda H" sort="Toy, Linda H" uniqKey="Toy L" first="Linda H." last="Toy">Linda H. Toy</name></author><author><name sortKey="Green Arsons, Alison" sort="Green Arsons, Alison" uniqKey="Green Arsons A" first="Alison" last="Green-Parsons">Alison Green-Parsons</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:43D87D635E85569AC4336AD7D0810A59D634441D</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1002/mds.870050407</idno><idno type="url">https://api.istex.fr/document/43D87D635E85569AC4336AD7D0810A59D634441D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F74</idno><idno type="wicri:Area/Istex/Curation">001F74</idno><idno type="wicri:Area/Istex/Checkpoint">004360</idno><idno type="wicri:doubleKey">0885-3185:1990:Cedarbaum:sustained:release:phno</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:1979657</idno><idno type="wicri:Area/PubMed/Corpus">004F41</idno><idno type="wicri:Area/PubMed/Curation">004F41</idno><idno type="wicri:Area/PubMed/Checkpoint">004E74</idno><idno type="wicri:Area/Ncbi/Merge">002841</idno><idno type="wicri:Area/Ncbi/Curation">002841</idno><idno type="wicri:Area/Ncbi/Checkpoint">002841</idno><idno type="wicri:doubleKey">0885-3185:1990:Cedarbaum J:sustained:release:phno</idno><idno type="wicri:Area/Main/Merge">009605</idno><idno type="wicri:Area/Main/Curation">006271</idno><idno type="wicri:Area/Main/Exploration">006271</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation</title><author><name sortKey="Cedarbaum" sort="Cedarbaum" uniqKey="Cedarbaum" last="Cedarbaum">Cedarbaum</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson and Movement Disorders Clinic, Department of Neurology and Neuroscience, Cornell University Medical College, the Burke Rehabilitation Center, White Plains, and the New York Hospital, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Clark, Mary" sort="Clark, Mary" uniqKey="Clark M" first="Mary" last="Clark">Mary Clark</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson and Movement Disorders Clinic, Department of Neurology and Neuroscience, Cornell University Medical College, the Burke Rehabilitation Center, White Plains, and the New York Hospital, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Toy, Linda H" sort="Toy, Linda H" uniqKey="Toy L" first="Linda H." last="Toy">Linda H. Toy</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson and Movement Disorders Clinic, Department of Neurology and Neuroscience, Cornell University Medical College, the Burke Rehabilitation Center, White Plains, and the New York Hospital, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Green Arsons, Alison" sort="Green Arsons, Alison" uniqKey="Green Arsons A" first="Alison" last="Green-Parsons">Alison Green-Parsons</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson and Movement Disorders Clinic, Department of Neurology and Neuroscience, Cornell University Medical College, the Burke Rehabilitation Center, White Plains, and the New York Hospital, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990">1990</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="298">298</biblScope><biblScope unit="page" to="303">303</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">43D87D635E85569AC4336AD7D0810A59D634441D</idno><idno type="DOI">10.1002/mds.870050407</idno><idno type="ArticleID">MDS870050407</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Antiparkinson Agents</term><term>Brain (drug effects)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (adverse effects)</term><term>Delayed-Action Preparations</term><term>Dopamine Agents</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Oxazines (administration & dosage)</term><term>Oxazines (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine D2</term><term>Response fluctuation</term><term>Therapeutics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Carbidopa</term><term>Levodopa</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antiparkinson Agents</term><term>Delayed-Action Preparations</term><term>Dopamine Agents</term><term>Drug Combinations</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Thérapeutique</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Humans</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">4‐‐Propyl‐9‐hydroxynaphthoxazine, or MK‐458 (HPMC), a selective, nonergot D2 agonist administered orally twice a day in sustained‐release form, was studied as adjunctive therapy with carbidopa‐levodopa (Sinemet) in 12 Parkinson's disease patients with motor response fluctuations. The dosage of agonist was gradually increased over 12 weeks to a maximum tolerated level of up to 60 mg/day, and that of Sinemet was reduced concurrently. After 8 weeks, reduction of Sinemet averaged 45.1%, but over the next 4 weeks, despite a continued increase in dosage of the agonist, patients were unable to decrease their Sinemet further, and by 12 weeks mean reduction in Sinemet was only 32%. Only five patients completed the planned 24‐week study, mostly due to progressive loss of efficacy. The MK‐458 is capable of partially substituting for Sinemet in dosages employed in this study. Reduced sensitivity to the drug can appear over a relatively short time, perhaps as a result of downregulation of postsynaptic dopamine receptors.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Cedarbaum" sort="Cedarbaum" uniqKey="Cedarbaum" last="Cedarbaum">Cedarbaum</name></region><name sortKey="Clark, Mary" sort="Clark, Mary" uniqKey="Clark M" first="Mary" last="Clark">Mary Clark</name><name sortKey="Green Arsons, Alison" sort="Green Arsons, Alison" uniqKey="Green Arsons A" first="Alison" last="Green-Parsons">Alison Green-Parsons</name><name sortKey="Toy, Linda H" sort="Toy, Linda H" uniqKey="Toy L" first="Linda H." last="Toy">Linda H. Toy</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006271 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006271 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:43D87D635E85569AC4336AD7D0810A59D634441D
|texte= Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
}}
| This area was generated with Dilib version V0.6.23. |  |